VNDA stock news · Vanda Pharmaceuticals Inc.
Get alerts for VNDA
Follow Vanda Pharmaceuticals Inc. (VNDA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VNDAVanda Pharmaceuticals has signed a deal to settle a patent dispute, letting MSN sell a generic version of HETLIOZ LQ.
Good for VNDAVanda settled a patent case, allowing MSN to sell its generic version starting in Q1 2040, with earlier entry possible in some cases. This favors Vanda by delaying competition.
Vanda Pharmaceuticals says its new anxiety drug didn’t meet key goals in testing.
Bad for VNDAVanda's Phase 3 anxiety-drug study missed its main and second goals, failing to confirm earlier encouraging results. This weakens the outlook for VQW-765.
12 health care stocks changed a lot in prices after the market closed on Wednesday.
NeutralVanda Pharmaceuticals shares fell 9.72% to $3.81 after hours, but the report gives no company news, so the business view is unchanged.
Vanda hopes to be the first to get a drug approved for people with sleep problems.
Good for VNDAVanda reported that HETLIOZ helped adults fall asleep earlier in a Phase 3 trial. The result supports a favorable outlook, though FDA approval is still pending.